Core Viewpoint - Viking Therapeutics Inc. is approaching a critical technical moment as its stock hovers near a potential death cross, indicating bearish signals and growing pressure on the stock despite previous rallies [1][2]. Stock Performance - VKTX stock experienced a significant decline, dropping 25.69% over the past month and 14.57% over the last six months, currently trading at $54.51, which is below its 20-day and 50-day simple moving averages of $58.72 and $63.04 respectively [2]. - The 200-day simple moving average is at $62.73, indicating a narrow gap that brings the death cross closer [3]. Technical Indicators - The Moving Average Convergence Divergence (MACD) indicator is at a negative 3.68, and the Relative Strength Index (RSI) is at 42.11, suggesting a loss of bullish momentum in the market [3]. Competitive Landscape - Analysts express concerns regarding Viking's ability to compete in the lucrative obesity drug market, which is dominated by major players like Eli Lilly and Novo Nordisk. The production scaling for both oral and injectable versions of Viking's weight-loss drug candidates may be costly and time-consuming, impacting short-term prospects [4]. Outlook - The impending death cross reflects broader challenges for Viking, as investor confidence diminishes amid sector-wide issues. However, there is potential for the stock to recover if Viking announces favorable clinical updates or strategic advancements in its weight-loss pipeline [5].

It has been about a month since the last earnings report for Viking Therapeutics, Inc. (VKTX) . Shares have lost about 29.5% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Viking Therapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Narrower-Than-Expecte ...

Shares of Viking Therapeutics (VKTX) have lost nearly 17% in the past month, translating to about $1.2 billion in market value, compared with the industry’s 7.1% decline. The stock has also underperformed the sector and the S&P 500 during the same period, as shown in the chart below. VKTX’s shares are trading below the 50 and 200-day moving averages.VKTX Stock Underperforms Industry, Sector & S&P 500 Image Source: Zacks Investment ResearchThough this biotech’s progress with its obesity drug program has been ...

On Tuesday, Viking Therapeutics, Inc. VKTX highlighted the final results from its VOYAGE Phase 2b trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH, also referred to as metabolic dysfunction-associated steatohepatitis, MASH) at the American Association for the Study of Liver Disease.Reduction in Liver Fat Content at 52 Weeks: Patients receiving VK2809 demonstrated statistically significant reductions in liver fat at Week 12, the primary endpoint.Patients receiving VK2809 ...

Oral Late Breaker Presentation Summarizes Positive Results Including Successful Achievement of Study's Primary and Secondary EndpointsData Support VK2809's Best-in-Class Profile Highlighted by Robust Liver Fat Reductions, Histologic Results Demonstrating NASH/MASH Resolution and Fibrosis Improvement, and Promising Tolerability and SafetySAN DIEGO, Nov. 19, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel ...

There aren't many biotechs that are more exciting than Viking Therapeutics (VKTX -7.45%) right now. Thanks to its clinical-stage candidate for weight loss, there's a real chance that this competitor could see its shares soar for years.But that doesn't mean you should rush to buy the stock without understanding what else is going on with this stock and why it's making the changes it's making. Let's examine three things you'll need to factor into your decision if you plan on investing in Viking Therapeutics t ...

Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (VKTX -7.45%), a mid-cap biotech that rose in prominence this year. The drugmaker's shares are up by nearly 200% since January.However, while many investors are excited about Viking's prospects, others worry they have already missed the boat. How much upside does a clinical-stage biotech with a market cap of $6.3 billion have? Is it too late to invest in Viking Therapeutics, or do the company's shares rem ...

Mergers and acquisitions could make a comeback with Trump headed back to Washington.The 2024 presidential election and President-elect Donald Trump is headed back to Washington. The Republican party also won control of the Senate and the House of Representatives.If Trump's previous tenure in the Oval Office is an indicator for what can be expected, there's a good chance for a less stringent regulatory environment.One of my big predictions under a Trump presidency is that mergers and acquisitions (M&A) will ...

Viking Therapeutics just revealed a new plan that could make waves in the weight loss industry.So far this year, Eli Lilly (LLY 0.54%) has been on an absolute tear and is swiftly becoming the world's most prolific pharmaceutical operation in my eyes. In addition to the unprecedented growth of its diabetes and obesity care treatments, Lilly has also secured some major wins from the Food and Drug Administration (FDA), including approval for both its Alzheimer's disease candidate and eczema drug.While it looks ...

Core Insights - Viking Therapeutics, Inc. announced that results from its Phase 2b clinical trial of VK2809 will be presented at the 75th Liver Meeting® 2024, focusing on nonalcoholic steatohepatitis (NASH) [1][2] Company Overview - Viking Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for metabolic and endocrine disorders, with three compounds currently in clinical trials [4] - The company leverages its expertise in metabolism to create innovative therapeutics aimed at improving patient outcomes [4] VK2809 Details - VK2809 is an orally available, selective thyroid hormone receptor beta agonist with a focus on liver tissue, showing potential in treating lipid disorders [3] - The Phase 2b VOYAGE study of VK2809 successfully met both primary and secondary endpoints in patients with biopsy-confirmed NASH and fibrosis [3] - In a Phase 2a study, VK2809 demonstrated significant reductions in LDL-C and liver fat content compared to placebo in patients with non-alcoholic fatty liver disease (NAFLD) [4] Upcoming Presentation - The oral presentation titled "Results from the 52-Week Phase 2b VOYAGE Trial of VK2809 in Patients with Biopsy-Confirmed NonAlcoholic Steatohepatitis and Fibrosis" will be delivered by Dr. Rohit Loomba on November 19, 2024, at the San Diego Convention Center [2]